The Weekly Roundup: April 15-19

Credit: Dermatology Times

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

QUIZ: Test Your Knowledge of Rosacea Complications and Comorbidities

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

My Colleague Has Defamed Me Online: What Can I Do?

What are your rights in the instance a colleague defames you online or on social media? David Goldberg, MD, JD, shares legal advice in our April issue.

Partner Q&A: Spherix Global Insights' Role in Shaping the Future of Dermatology

Dermatology Times is pleased to introduce one of our newest partners, Spherix Global Insights. Learn more about their vision and plans to leverage knowledge to support dermatology.

Dermatology Residency Programs Lack Specific, Comprehensive Education on Sensitive Skin

Research from the GW School of Medicine and Health Sciences was recently published in the Journal of Drugs in Dermatology.

Is Your Texting as Caring as Your Bedside Manner?

Test your knowledge to see if your patients would consider you an efficient texter.

Reviewing the Rosacea Pipeline: A Look at the Last 10 Years

In recognition of Rosacea Awareness Month, Dermatology Times is reviewing research and strides in rosacea treatment over the last decade.

New AAD Atopic Dermatitis Guidelines and Dupilumab Label Updates

Five experts delved into the latest updates to treatment guidelines and the updated label use for dupilumab for hand-foot AD.

FDA Issues Alert on Counterfeit Botox: What Dermatology Clinicians Need to Know

The FDA has released guidelines for clinicians and tips to identify the distinguishing features of counterfeit products.

In Interim Analysis, Mogamulizumab Demonstrates Improvements In Mycosis Fungoides, Sézary Syndrome

Interim findings from the PROSPER study of mogamulizumab in adults with CTCL were recently presented orally.

Secukinumab Demonstrates Promise for Patients With Severe Hidradenitis Suppurativa Who Found Adalimumab Intolerable

A study demonstrated the favorable efficacy and safety profiles of secukinumab in patients with severe HS for up to 52 weeks.

A Novel Approach to Distinguishing Scabies From Atopic Dermatitis

The WHO underscores the significance of addressing scabies as a neglected skin disease, especially in regions with limited health care access.

Experts Pen 12 Implementable Steps For Addressing Gender Inequity In Academic Dermatology

Addressing gender inequity in academic dermatology involves strengthening societies, celebrating female dermatologists, promoting leadership, and equitable representation, authors wrote.

New Dermatology Social Comparison Scale Demonstrates Acceptable Psychometrics for Clinical and Research Applications

Researchers recently developed and validated the 3-question social comparison scale, which may be applicable outside of conditions such as eczema and psoriasis.

Pointers With Portela: Minimalist Skin Care Routines

In this week’s Pointers With Portela, the 208SkinDoc discusses the effectiveness of a minimalist anti-aging skin care routine for patients.

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization

Data stems from week 28 results of the German G-EPOSS study evaluating the effectiveness of guselkumab in skin health, quality of life, sexuality, and stigmatization.

Variable-Sequenced Large-Spot KTP and PDL Demonstrate Comparable Efficacy in Rosacea

Researchers compared a variable-sequenced, large-spot 532 nm KTP laser to the 595 nm pulsed-dye laser.

Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Researchers noted that further examination and monitoring for headache disorders in patients with atopic dermatitis may be warranted.

Introducing Omar Noor, MD, FAAD: Dermatology Times' Newest Editorial Advisory Board Member

Noor, the co-owner of Rao Dermatology, shares about his interests in dermatology and what he most looks forward to as a member of our board.

Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients

Scurto presented integrative medicine pearls at the 2024 Diversity in Dermatology meeting.

Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says

Researchers examined local skin reactions of a topical gel inhibiting cytosolic phospholipase A2 both in-clinic and remotely.

QUIZ RECAP: Test Your Knowledge of Rosacea Complications and Comorbidities

Earlier this week, we shared our second Rosacea Awareness Month quiz. Review the answers and your responses below.

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

A recent review and meta-analysis says this statistic may be due in part to nocebo effects.

Tracee Blackburn, PA-C: Gut Health for Healthy Skin

Blackburn presented integrative medicine pearls on gut and hormone health at the 2024 Diversity in Dermatology meeting.